Kucuksezer Umut C, Ozdemir Cevdet, Akdis Mübeccel, Akdis Cezmi A
Department of Immunology, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey.
Department of Pediatric Allergy, Atasehir Hospital, Memorial Health Group, Istanbul, Turkey.
Korean J Pediatr. 2013 Dec;56(12):505-13. doi: 10.3345/kjp.2013.56.12.505. Epub 2013 Dec 20.
Because the prevalence of allergic diseases has significantly increased in recent years, understanding the causes and mechanisms of these disorders is of high importance, and intense investigations are ongoing. Current knowledge pinpoints immune tolerance mechanisms as indispensable for healthy immune response to allergens in daily life. It is evident that development and maintenance of allergens-pecific T cell tolerance is of vital importance for a healthy immune response to allergens. Such tolerance can be gained spontaneously by dose-dependent exposures to allergens in nature or by allergen-specific immunotherapy. Allergen-specific immunotherapy induces regulatory T cells with the capacity to secrete interleukin-10 and transforming growth factor-β, limits activation of effector cells of allergic inflammation (such as mast cells and basophils), and switches antibody isotype from IgE to the noninflammatory type IgG4. Although allergen-specific immunotherapy is the only method of tolerance induction in allergic individuals, several factors, such as long duration of treatment, compliance problems, and life-threatening side effects, have limited widespread applicability of this immunomodulatory treatment. To overcome these limitations, current research focuses on the introduction of allergens in more efficient and safer ways. Defining the endotypes and phenotypes of allergic diseases might provide the ability to select ideal patients, and novel biomarkers might ensure new custom-tailored therapy modalities.
近年来,由于过敏性疾病的患病率显著上升,了解这些疾病的病因和发病机制至关重要,目前正在进行深入研究。目前的知识表明,免疫耐受机制对于日常生活中对过敏原的健康免疫反应不可或缺。显然,过敏原特异性T细胞耐受性的形成和维持对于对过敏原的健康免疫反应至关重要。这种耐受性可以通过在自然环境中依赖剂量接触过敏原或通过过敏原特异性免疫疗法自发获得。过敏原特异性免疫疗法可诱导分泌白细胞介素-10和转化生长因子-β的调节性T细胞,限制过敏性炎症效应细胞(如肥大细胞和嗜碱性粒细胞)的激活,并将抗体亚型从IgE转换为非炎症性IgG4。尽管过敏原特异性免疫疗法是诱导过敏个体产生耐受性的唯一方法,但治疗时间长、依从性问题和危及生命的副作用等几个因素限制了这种免疫调节治疗的广泛应用。为了克服这些局限性,目前的研究重点是以更有效、更安全的方式引入过敏原。确定过敏性疾病的内型和表型可能有助于选择理想的患者,新的生物标志物可能确保新的定制治疗模式。